Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia
Hong, Xiaohong1,2; Chan, Raymond C. K.1,3; Zhuang, Xihang2; Jiang, Tingyun2; Wan, Xiaona2; Wang, Junqing2; Xiao, Bo2; Zhou, Hanhui2; Jiang, Liyun2; Weng, Bilan2; X. H. Hong; R. C. K. Chan
2009-03-01
发表期刊SCHIZOPHRENIA RESEARCH
ISSN0920-9964
文章类型Article
卷号108期号:1-3页码:151-157
摘要Sensory gating deficit, as reflected by P50 suppression, has been demonstrated in schizophrenia. Despite extensive evidence of the irreversible effects of typical neuroleptics on this deficit, recent studies of atypical neuroleptics have produced inconsistent findings on the reversibility of P50 suppression in schizophrenia. As the majority of these studies were limited by either their cross-sectional design or the recruitment of patients on multiple medications, the current Study was designed to examine the effects of different neuroleptic medications on the P50 sensory gating index in patients with first-episode, never-medicated schizophrenia. P50-evoked potential recordings were obtained from 62 normal controls when they entered the study and from 65 patients with first-episode, never-medicated schizophrenia at baseline and after six weeks of different neuroleptic treatments (sulpiride [n=241, risperidone [n=24] and clozapine [n-17]). The first-episode, never-medicated schizophrenia patients had impaired sensory gating relative to the normal controls (mean-94.19% [SD = 61.31%] versus mean=41.22% [SD-33.82%]). The test amplitude S2 was significantly higher in the schizophrenia patients than in the normal controls. The conditioning amplitude S1 and the positive symptom scores were related to the P50 gating ratios in schizophrenia at baseline. There was no change in P50 sensory gating (P>0.10) and a significant improvement in the clinical ratings (P>0.10) after six-week neuroleptic treatment for schizophrenia. P50 sensory gating was not significant for the patients who received sulpiride, risperidone or clozapine at baseline (F=1,074, df = 2, 62, P=0.348)or at endpoint (F=0.441, df=2,62, p=0.646). Our findings indicate that there is P50 sensory gating impairment in first-episode, nevermedicated schizophrenia and that treatment with typical and atypical antipsychotics has no significant impact on such gating in this illness.; Sensory gating deficit, as reflected by P50 suppression, has been demonstrated in schizophrenia. Despite extensive evidence of the irreversible effects of typical neuroleptics on this deficit, recent studies of atypical neuroleptics have produced inconsistent findings on the reversibility of P50 suppression in schizophrenia. As the majority of these studies were limited by either their cross-sectional design or the recruitment of patients on multiple medications, the current Study was designed to examine the effects of different neuroleptic medications on the P50 sensory gating index in patients with first-episode, never-medicated schizophrenia. P50-evoked potential recordings were obtained from 62 normal controls when they entered the study and from 65 patients with first-episode, never-medicated schizophrenia at baseline and after six weeks of different neuroleptic treatments (sulpiride [n=241, risperidone [n=24] and clozapine [n-17]). The first-episode, never-medicated schizophrenia patients had impaired sensory gating relative to the normal controls (mean-94.19% [SD = 61.31%] versus mean=41.22% [SD-33.82%]). The test amplitude S2 was significantly higher in the schizophrenia patients than in the normal controls. The conditioning amplitude S1 and the positive symptom scores were related to the P50 gating ratios in schizophrenia at baseline. There was no change in P50 sensory gating (P>0.10) and a significant improvement in the clinical ratings (P>0.10) after six-week neuroleptic treatment for schizophrenia. P50 sensory gating was not significant for the patients who received sulpiride, risperidone or clozapine at baseline (F=1,074, df = 2, 62, P=0.348)or at endpoint (F=0.441, df=2,62, p=0.646). Our findings indicate that there is P50 sensory gating impairment in first-episode, nevermedicated schizophrenia and that treatment with typical and atypical antipsychotics has no significant impact on such gating in this illness. (C) 2008 Elsevier B.V. All rights reserved.
关键词Sensory gating P50 First-episode schizophrenia
学科领域精神病学 ; 认知神经科学
收录类别SCI ; SSCI
语种英语
WOS记录号WOS:000264506500019
引用统计
被引频次:34[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.psych.ac.cn/handle/311026/5581
专题中国科学院心理研究所回溯数据库(1956-2010)
通讯作者X. H. Hong; R. C. K. Chan
作者单位1.Chinese Acad Sci, Inst Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Beijing 100101, Peoples R China
2.Shantou Univ, Coll Med, Mental Hlth Ctr, Shantou, Peoples R China
3.Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China
推荐引用方式
GB/T 7714
Hong, Xiaohong,Chan, Raymond C. K.,Zhuang, Xihang,et al. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia[J]. SCHIZOPHRENIA RESEARCH,2009,108(1-3):151-157.
APA Hong, Xiaohong.,Chan, Raymond C. K..,Zhuang, Xihang.,Jiang, Tingyun.,Wan, Xiaona.,...&R. C. K. Chan.(2009).Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.SCHIZOPHRENIA RESEARCH,108(1-3),151-157.
MLA Hong, Xiaohong,et al."Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia".SCHIZOPHRENIA RESEARCH 108.1-3(2009):151-157.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Hong-2009-Neurolepti(270KB) 开放获取--请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hong, Xiaohong]的文章
[Chan, Raymond C. K.]的文章
[Zhuang, Xihang]的文章
百度学术
百度学术中相似的文章
[Hong, Xiaohong]的文章
[Chan, Raymond C. K.]的文章
[Zhuang, Xihang]的文章
必应学术
必应学术中相似的文章
[Hong, Xiaohong]的文章
[Chan, Raymond C. K.]的文章
[Zhuang, Xihang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。